financetom
Business
financetom
/
Business
/
JPMorgan, Greek fintech, claim success in London court
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
JPMorgan, Greek fintech, claim success in London court
Jun 13, 2024 11:11 AM

LONDON (Reuters) - Wall Street bank JP Morgan and Greek fintech boss Haris Karonis both claimed success on Thursday in a London court battle over how to value a joint business, paving the way for its potential sale.

Karonis's WEREALIZE.COM (WRL), the majority owner of Athens-based Viva Wallet, has accused JP Morgan of trying to hamper the growth of the payments platform and both sides sued each other in London.

But a London judge dismissed suggestions that JP Morgan had any incentive to depress Viva's value and set out how the business should be valued, a judgment published on Thursday showed.

The U.S. bank bought a 48.5% stake in Viva Wallet, which is used by businesses in southern Europe, for about $800 million in 2022. WRL owns 51.49%.

Under the terms of the deal, WRL loses its right to reject any JP Morgan offer to take control of Viva if the business is valued at below 5 billion euros ($5.4 billion) by July 30, 2025.

"As the founder of this business, I am thrilled that Viva will now be properly valued on the basis of its growth strategy in the U.S., reflecting its fair market value," Karonis said in a statement.

JP Morgan said it remained committed to developing and expanding Viva in partnership with WRL, adding that the judgment was a "great outcome".

"With a financial stake in the company, we have repeatedly offered ways to help the company expand and succeed. The court has now provided a critical step to move forward with fair and transparent valuations - which could allow Viva to be sold soon, before the Fintech M&A market further softens," a JP Morgan spokesperson said.

($1 = 0.9315 euros)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved